Abstract Immune-mediated diseases are common and lifethreatening disorders in dogs. Many canine immunemediated diseases have strong breed predispositions and are believed to be inherited. However, the genetic mutations that cause these diseases are mostly unknown. As many immune-mediated diseases in humans share polymorphisms among a common set of genes, we conducted a candidate gene study of 15 of these genes across four immune-mediated diseases (immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, immunemediated polyarthritis (IMPA), and atopic dermatitis) in 195 affected and 206 unaffected dogs to assess whether causative or predictive polymorphisms might exist in similar genes in dogs. We demonstrate a strong association (Fisher's exact p = 0.0004 for allelic association, p = 0.0035 for genotypic association) between two polymorphic positions (10 bp apart) in exon 2 of one allele in DLA-79, DLA-79*001:02, and multiple immune-mediated diseases. The frequency of this allele was significantly higher in dogs with immune-mediated disease than in control dogs (0.21 vs. 0.12) and ranged from 0.28 in dogs with IMPA to 0.15 in dogs with atopic dermatitis. This allele has two non-synonymous substitutions (compared with the reference allele, DLA-79*001:01), resulting in F33L and N37D amino acid changes. These mutations occur in the peptide-binding pocket of the protein, and based upon our computational modeling studies, are likely to affect critical interactions with the peptide N-terminus. Further studies are warranted to confirm these findings more broadly and to determine the specific mechanism by which the identified variants alter canine immune system function.
Introduction
Immune-mediated diseases such as immune-mediated hemolytic anemia (IMHA), immune-mediated thrombocytopenia (ITP), and type I diabetes (T1D) are common and lifethreatening conditions in dogs with short-term mortality rates as high as 50 % (Carr et al. 2002; O'Marra et al. 2011) . Most immune-mediated diseases result from an aberrant immune system response in which normal defense mechanisms attack the body's own cells, tissues, and organs (Temajo and Howard 2014) . Therapy for many of these diseases in dogs involves blanket suppression of the immune system, which can cause complications ranging from polyuria to severe secondary infections (Whitley and Day 2011) . Other immune-mediated diseases require lifelong supplementation to replace hormones such as insulin, pancreatic enzymes, or mineralocorticoids, requiring strict compliance and regular monitoring that can be burdensome for owners and patients alike. For all of these reasons, finding ways to decrease the prevalence of immunemediated disorders is an important challenge in canine medicine.
Many immune-mediated diseases in dogs have strong breed associations and are believed to be inherited (Famula et al. 2003; Chase et al. 2006; Wilbe et al. 2010a, c; Salzmann et al. 2011; Wang et al. 2011; Pedersen et al. 2012a; Massey et al. 2014) . One approach to decreasing the frequency of these diseases involves breeding programs that consider the role of predisposing genetic polymorphisms. In humans, variants in a common group of genes are believed to contribute to the development of many different immune-mediated diseases (Cho and Gregersen 2011; Voight and Cotsapas 2012; Cotsapas and Hafler 2013; Castiblanco et al. 2013; Parkes et al. 2013; Sorrentino 2013) . Analysis of this network of genes has led to the theory that an accumulated burden of genetic variants causes an underlying predisposition to multiple immune-mediated diseases (Cotsapas et al. 2011; Gregersen et al. 2012; Cotsapas and Hafler 2013) . Some of these genes, such as the major histocompatibility complex (MHC) class II genes, PTPN22, and CTLA4, have been associated with specific canine immune-mediated diseases (Kennedy et al. 2006b; Kennedy et al. 2006a; Short et al. 2010; Greer et al. 2010; Barber et al. 2011; Massey et al. 2013a, b; Catchpole et al. 2013; Short et al. 2013; Schrauwen et al. 2014) , but the importance of broader gene networks across multiple immune-mediated diseases is not well understood in dogs.
In this study, we hypothesized that given the commonality of variants across immune-mediated diseases in humans, a candidate gene approach could allow us to identify polymorphisms that are common to multiple immune-mediated diseases in dogs. We identified 15 candidate genes that have been associated with multiple immune-mediated diseases in humans and sequenced them initially in 16 dogs of different breeds with IMHA. Based upon our findings suggesting an association between IMHA and a non-synonymous variant in the canine MHC class Ib gene DLA-79, we evaluated this variant in a total of 195 dogs with various immune-mediated diseases and 206 dogs without immune-mediated disease across 24 breeds. Our findings support a strong association of this non-synonymous variant in DLA-79 with multiple immune-mediated diseases in dogs.
Methods

Animal selection and phenotyping
We initially selected 16 dogs with IMHA for targeted resequencing of 15 candidate genes (see below) and validated our findings in 12 additional dogs with IMHA (Fig. 1) . We then selected an additional 173 dogs with various immunemediated diseases for further genotyping (Fig. 1) . We included 195 dogs across 24 breeds with 4 immune-mediated diseases in the final analysis. These included: 94 dogs with IMHA, 41 dogs with immune-mediated thrombocytopenia (ITP), and 16 dogs with immune-mediated polyarthritis (IMPA) as examples of autoimmune diseases, and 44 dogs with atopic dermatitis (AD) as an example of an environmentally triggered immune-mediated disease. Six affected dogs were eliminated from the final analysis in order to balance within-breed cases and controls. In order to include samples from a particular dog breed in the final analysis, we required at least three withinbreed cases and two breed-matched controls across all diseases.
Dogs with IMHA, ITP, and IMPA were selected from inpatient or outpatient populations at veterinary referral hospitals at North Carolina State University, The Ohio State University, Tufts University, and Cornell University; dogs with AD were recruited through referral veterinary dermatologists and breed clubs across the USA. Diagnoses of IMHA, Fig. 1 Flow of experiments performed in this study, including the number of dogs genotyped in each cohort, the genotyping technology employed, and the number of variants screened in each population. Of the dogs genotyped, 12 of the 16 dogs with IMHA in the targeted resequencing cohort, 10 of the 12 dogs with IMHA in validation cohort 1, and zero of the 22 control dogs in validation cohort 1 were included in the final analysis. Animals were removed from the final analysis in order to balance within-breed cases and controls ITP, and IMPA were confirmed by a diplomate of the American College of Veterinary Emergency and Critical Care or the American College of Veterinary Internal Medicine. Diagnosis of AD was confirmed by a diplomate of the American College of Veterinary Dermatology.
Inclusion criteria for dogs with IMHA were as follows: packed cell volume <30 %, spherocytosis or positive results on either a slide agglutination or direct Coombs test (minimum titer 1:64). Dogs with ITP were required to have a platelet count <20 × 10 9 /L, normal prothrombin time and partial thromboplastin time, and absence of significant active hemorrhage based upon physical examination or ultrasonographic cavitary fluid assessment. For dogs with IMPA, inclusion criteria were at least two joints containing a synovial fluid white blood cell count >3 × 10 9 /L with at least 10 % neutrophils and no observed intracellular or extracellular bacteria (as determined by a board-certified veterinary clinical pathologist), as well as radiographic evidence demonstrating nonerosive articular disease in the joints sampled. Dogs with IMHA, ITP, or IMPA were excluded if they had any of these concurrent conditions: evidence of neoplasia on thoracic radiographs, evidence of neoplasia on abdominal ultrasound, presence of foreign metallic objects on abdominal radiographs, evidence of true infection with erythrocyte-borne or rickettsial disease based upon blood smear, blood culture, convalescent immunofluorescent assay, or polymerase chain reaction (PCR). Inclusion criteria for dogs with IMHA, ITP, and IMPA were similar to those described elsewhere (Clements et al. 2004; Weinkle et al. 2005; Huang et al. 2012) . Dogs with AD were diagnosed as described previously (Salzmann et al. 2011) . A summary of all 195 animals with immune-mediated disease included in the final analysis is provided in Table 1 .
We also included 206 dogs across the same 24 breeds without immune-mediated disease as controls (Fig. 1) . Dogs without immune-mediated disease included 67 dogs with neurologic disease (primarily intervertebral disc disease, central nervous system neoplasms, or congenital malformations), 56 healthy dogs, 52 dogs with cardiac disease (primarily dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, myxomatous mitral valve disease, or a congenital structural abnormality), 14 dogs with non-immune-mediated endocrine disorders, 12 dogs with corneal ulcers, and 5 dogs with gastrointestinal disease. These dogs are also described in Table 1 .
Candidate gene selection
We reviewed meta-analyses of the genes involved in human immune-mediated disease and tabulated the frequency that each gene was associated with a disease (Cotsapas et al. 2011; Cho and Gregersen 2011; Visscher et al. 2012; Castiblanco et al. 2013) . We also accessed the protein-coding genes from ImmunoBase version 1.7 (www.immunobase.org) and included these in our analysis (Parkes et al. 2013) . After developing a preliminary list of candidate genes based upon the frequency of association with human autoimmune disease, we cross-referenced our findings with genes that have been implicated in canine immune-mediated diseases, including IMHA, T1D, and systemic lupus erythematosus (Wilbe et al. 2009 (Wilbe et al. , 2010c Pedersen et al. 2012a, b; Massey et al. 2013a; Catchpole et al. 2013; Short et al. 2013) . We ultimately selected 15 of these genes for targeted resequencing, which represented the maximum number of genes that could be covered within a 500 Kb capture region. The final list of 15 candidate genes selected is provided in Table 2 .
DNA isolation
Whole venous blood was obtained from each animal in ethylenediaminetetraacetic acid (EDTA). Genomic DNA samples were prepared by either phenol-chloroform or column-based extraction. For phenol-chloroform extraction, cells were osmotically lysed in 2× sucrose-Triton (pH 7.6), Tris-NH 4 Cl buffer (pH 7.2) and nuclei were pelleted by centrifugation (2000 g for 20 min at 25°C). Pellets were resuspended in saline-EDTA (pH 8.0) with 20 % SDS and proteinase K, and incubated overnight at 56°C. Samples were subjected to one phenol-chloroform-isoamyl alcohol (25:24:1, pH 8) and one chloroform extraction. Finally, the DNA was precipitated (95-100 % ethanol and 2 M NaCl), and resuspended in 100-200 μL of nuclease-free water. Column-based extraction was performed using a commercially available kit (QIAamp Midi Kit, Qiagen, Valencia, CA).
Next-generation sequencing
Targeted resequencing was performed in 16 dogs with IMHA (TR genotyping cohort, Online Resource 1). Sequencing libraries were prepared from genomic DNA (approximately 3 μg/dog) using the SureSelectXT Custom MP4 Kit (Agilent Technologies, Santa Clara, CA). The kit contained a custom capture library of 11,117 RNA baits 121 bp in length and designed based on the CanFam3.1 reference sequence. The library was designed to capture both the exons and introns of each gene plus approximately 10 % additional bases 5′ and 3′ to each gene, totaling 484,219 base pairs (bp). Baits were designed to give 2× coverage and exclude repeat-masked regions, resulting in coverage of 88.6 % (368,234 bp). Library preparation was performed using the Accel-NCS 2S DNA Library Kit for Illumina (Swift Biosciences, Ann Arbor, MI), followed by probe hybridization and target enrichment per the SureSelectXT protocol. Shearing of genomic DNA was performed using a Covaris E220 ultrasonicator (Woburn, MA); library size and quality were analyzed using the LabChip GX microfluidics capillary electrophoresis system (PerkinElmer, Waltham, MA) according to manufacturer recommendations. Paired-end sequencing resulting in 150 bp paired-end reads was conducted in a single flowcell on an Illumina MiSeq Desktop Sequencer (San Diego, CA), performed by the High Throughput Sequencing Facility at the University of North Carolina at Chapel Hill. Sequence reads were trimmed using Trimmomatic 0.32 to a minimum phred-scaled base quality score of 30 at the start and end of each read with a minimum read length of 70 bp, and the resulting reads were aligned to the CanFam3.1 reference sequence using BWA 0.7.10 (Li and Durbin 2009; Bolger et al. 2014) . Aligned reads were prepared for analysis using GATK 3.3-0 following the best practices for base quality score recalibration and indel realignment specified by the Broad Institute, Cambridge, MA. HaplotypeCaller was used to call SNP and indel variants (McKenna et al. 2010; DePristo et al. 2011; Van der Auwera et al. 2013 ). Reads were visualized using GenomeBrowse 2.0.6 software (Golden Helix, Bozeman, MT). On-target reads generated across all 16 samples represented a 675-Mb dataset. Average read depth across the targeted region for all samples ranged from 70× to 122×, and approximately 90 % of the region was sequenced with at least 30× coverage.
Variant quality score recalibration was performed using GATK with canine SNPs from dbSNP 139 and SNPs on the Illumina CanineHD BeadChip used as training resources, with a tranche sensitivity cutoff of 99 % for passing variants. Variants were removed from the passing callset that were also present in a subset of 25 control dogs with inherited or acquired cardiac or neurologic abnormalities (five Great Danes, Cingolani et al. 2012 ).
Variant validation
Because our primary goal was to identify polymorphisms that contribute to disease across breeds, we selected the subset of variants present in at least 14 of 16 dogs with IMHA for further analysis. We also chose those variants that were likely to have an important structural or functional impact (based upon SnpEff and VEP predictions) and were present in at least a third of the dogs evaluated. We genotyped these variants in a separate cohort of 12 dogs with IMHA and 22 dogs without immune-mediated disease (genotyping cohort 1, Online Resource 1). Genotyping was performed using a custom Sequenom array and carried out by Neogene (Lincoln, NE) using standard protocols 1 with multiplexing at 24 SNPs per well. Genotype calls were made using Typer 4.0 software (Agena Bioscience, San Diego, CA).
We tested the Sequenom assay genotypes for association with immune-mediated disease and selected two variants that defined one allele, in exon 2 of DLA-79, for genotyping in a larger group of dogs. Our genotyping assay for DLA-79*001:02 is based on one or two of the seven polymorphic positions in exon 2 and none of the five polymorphic positions in exon 3. The assumption is that this assay will separate DLA-79*001:02 from the other five alleles that have been previously identified (Graumann et al. 1998; Venkataraman et al. 2013) . Genotyping was performed by either Sanger sequencing or an endpoint genotyping assay in an additional 173 dogs with various immune-mediated diseases and 206 control dogs (validation cohort 2, Online Resource 1). In selecting dogs for this cohort, we attempted to balance within-breed cases and controls from among the samples available at our hospitals.
For Sanger sequencing, amplicons were generated by PCR using primers F-5′-gcactccctgaggttcttga and R-5′-gtgtgcaggtcctggagttc with M13 forward and reverse sequences appended and were designed to generate a 209-bp fragment. PCR reaction conditions were as follows: 50 ng genomic DNA, 0.5 μM each primer, 1× AmpliTaq Gold 360 Master Mix (Life Technologies, Carlsbad, CA), 40 cycles, T m 60°C. PCR products were cleaned using ExoSAP-IT (Affymetrix, Santa Clara, CA) and sequenced by Sanger sequencing on an Applied Biosystems 3730 × l DNA Analyzer (Carlsbad, CA) using standard reaction conditions. Analysis of the resulting sequence trace files was performed using Geneious 8.0.5 (Biomatters Limited, Auckland, NZ).
For endpoint genotyping, we used HEX-or FAM-labeled locked nucleic acid probes to genotype at the first polymorphic position in exon 2. Primer sequences were F-5′-gaggttcttgaacacggtcg and R-5′-ctcttcccagtactcaggcc, and probe sequences for the wild-type and alternate allele were 5′-FAM-tTCGAaCGgtt and 5′-HEX-cgtTGGAaCgg, respectively. Both probe sequences had Iowa Black quenchers conjugated to the 3′ end. PCR reaction conditions were as follows: 50 ng genomic DNA, 0.5 μM each primer, 0.2 μM each probe, 1× LightCycler 480 Probes Master Mix (Roche Diagnostics, Indianapolis, IN), 40 cycles, T m 60°C. Fluorescence was detected using a Roche LightCycler 480 II real-time PCR system. A summary of the dogs, genotyping methods, and flow of experiments used in this study is provided in Fig. 1 .
Statistical analysis
In an effort to balance cases and controls by breed, we eliminated four dogs from the targeted resequencing cohort (all cases) and 24 dogs from validation cohort 1 (2 cases, 22 controls) from the final analysis as the breeds represented among these dogs did allow us to include at least 3 cases and 2 controls per breed. This left 401 dogs across 24 breeds (Table 1) for association testing in the final analysis. Phenotypes were analyzed in aggregate (all immune-mediated diseases vs. control) and by disease (IMHA, ITP, IMPA, AD, control). Allele and genotype frequencies were compared using 2 × n or 3 × n contingency tables and association with disease was tested using a χ 2 or Fisher's exact test with p < 0.05 considered significant. All statistical analyses were performed using JMP Pro 11 (SAS, Cary, NC).
Structural modeling
Structural models of the reference (DLA-79*001:01) and DLA-79*001:02 proteins were developed in order to predict the impact of the genetic variants being analyzed. Homology models of both the reference and DLA-79*001:02-containing protein were created with the SWISS-MODEL homology server using chain A, residues 1-276 of Protein Data Bank (PDB) 1Q94 as the template structure (Li and Bouvier 2004; Arnold et al. 2006; Kiefer et al. 2009; Guex et al. 2009; Biasini et al. 2014) . 1Q94 was chosen as the template because it had the highest sequence identity (69 %) of any deposited protein structure and because structure-based sequence alignment showed that the region of interest surrounding the mutation sites had the highest conservation compared with other available models. The template model is a protein structure of the human MHC class I allele HLA-A*1101. Ramachandran plots were generated by MolProbity as implemented in Phenix (Adams et al. 2010) . Models were also validated with the SWISS-MODEL Qmean server, which predicts the local error (in Angstroms) of individual residues based on solvent accessibility, secondary structure, and model geometry (Benkert et al. 2011 ).
Computational solvent mapping
Computational solvent mapping for the reference and DLA-79:001:02 homology models was performed using a protein only model of each structure input to FTMap (ftmap.bu.edu) (Brenke et al. 2009; Kozakov et al. 2011) . FTMap probes the protein surface with a defined set of small organic molecules; sites where significant clusters of organic solvents bind have been shown to correlate with ligand binding sites (Buhrman et al. 2011) . Organic solvent clusters for each protein were superimposed and examined in Coot (Emsley et al. 2010 ).
Computational peptide docking
DLA-79-binding sequences were predicted using NetMHCpan 2.8 (Nielsen et al. 2007; Hoof et al. 2009 ) to derive peptide antigens from proteins implicated in the pathogenesis of canine IMHA or ITP (erythrocyte membrane protein band 3 (EMPB3), glycophorin A and C, and platelet integrins) as inputs (Lewis and Meyers 1996; Corato et al. 1997; Day 1999; Callan et al. 2013) . NetMHCpan predicts peptide binding sequences and affinities to any MHC class I molecule using artificial neural networks, and is trained using inputs from human, mouse, pig, macaque, chimpanzee, gorilla, and cow MHC molecules and over 150,000 known peptide-protein interactions. Peptides that bind MHC class I molecules are typically 9-11 residues in length and are numbered from P1 at the N-terminus. Peptide sequences with a predicted protein binding affinity greater than 200 nM were selected for further evaluation (Online Resource 2) Peptide structures were then developed in Coot by mutating the bound peptide from the 1Q94 template to match the NetMHCpan peptide sequences. Peptide-protein complexes for the wild-type and mutant proteins were submitted to Rosetta FlexPepDock (flexpepdock.furmanlab.cs.huji.ac.il) (Raveh et al. 2010; London et al. 2011) . Rosetta FlexPepDock uses Monte Carlo simulation with energy minimization to optimize peptide-protein interactions and allows for multiple protein sidechain rotamer conformations, a flexible peptide backbone, and multiple peptide side-chain conformations. The ten lowest energy complexes for each peptide were examined directly in Coot and PyMOL.
2 Visual inspection of these complexes showed that peptides with a hydrophobic amino acid at P1 adopted a wider range of conformations in the reference vs. the DLA-79:001:02 structure. To quantitate conformational flexibility, we calculated the surface area occupied by all peptide conformations at the P1 position for both structures using AREAIMOL as implemented in the CCP4 suite (Lee and Richards 1971; Saff and Kuijlaars 1997) .
Results
Genotyping
We found 963 variants passing our filter criteria through targeted resequencing of 16 dogs with IMHA. Of these variants, 875 were intragenic. The effects of these variants were classified by SnpEff as follows: intron 658, upstream 84, downstream 51, 3′-UTR 42, non-synonymous coding 22, synonymous coding 12, splice site region 4, and splice site acceptor 1, 5′-UTR 1. STAT1 had by far the largest number of variants at 289, the vast majority of which were intronic (248). A summary of these 963 variants is provided in Online Resource 3.
We genotyped a subset of 22 of these variants (17 in at least 14 of 16 dogs and 5 in at least a third of dogs and predicted by SnpEff and VEP to have an important structural or functional impact) in a separate cohort of 34 dogs (validation cohort 1) and ruled out association with immune-mediated disease in all but two polymorphic SNPs in DLA-79. The DLA-79 polymorphisms are non-synonymous coding variants at chr18:41, 142,888 and 41,142,898 and lie within exon 2 of the gene (Fig. 2) . The former polymorphism is a C>G transversion and the latter an A>G transition. Coding DNA coordinates for these variants are c.186C>G and c.196A>G, respectively; c.186C>G causes an F33L substitution and c.196A>G causes a N37D substitution.
3 Together, these variants define the difference between the reference DLA-79 sequence and the DLA-79*001:02 allele that has been previously reported (Graumann et al. 1998; Venkataraman et al. 2013) and are in perfect linkage disequilibrium across all samples evaluated. We also noted an additional five polymorphisms (four upstream of DLA-79, one in intron 1 of DLA-79) in perfect linkage disequilibrium with DLA-79*001:02, but these variants were not validated beyond the original 16 dogs (Fig. 2) .
Since some genetic variants are common to many immunemediated diseases and because of the potentially wide-ranging effects of DLA genes, we validated the association of DLA-79*001:02 with multiple immune-mediated diseases in aggregate. Independent validation in a separate cohort of 173 dogs with immune-mediated disease (IMHA, ITP, IMPA, or AD) and 206 control dogs (validation cohort 2) showed strong association using both allelic and genotypic tests (Fisher's exact p = 0.001 for allelic association, p = 0.016 for genotypic association). Combined results of all 401 dogs also showed strong association with immune-mediated disease (Fisher's exact p = 0.0004 for allelic association, p = 0.0035 for genotypic association, Fig. 3 ). The DLA-79*001:02 allele frequency is 0.21 in patients with immune-mediated disease vs. 0.12 in patients without immune-mediated disease, and the relative risk of immune-mediated disease in patients with DLA-79*001:02 is 1.4 (95 % confidence interval 1.2-1.6). Across the four diseases studied, the DLA-79*001:02 allele frequencies were 0.28 for IMPA, 0.24 for ITP, 0.21 for IMHA, and 0.15 for AD.
We further examined contingency tables using phenotype data separated by each immune-mediated disease rather than in aggregate (Table 3 ). The observed distribution of diseases in both allelic and genotypic categories was different from the expected distribution using the omnibus χ 2 test (p = 0.0022 for allelic association, p = 0.04 for genotypic association), consistent with our findings for immune-mediated diseases in aggregate.
Structural and functional modeling
Homology models of the DLA-79 reference and DLA-79*001:02 proteins were prepared as described above in order to predict the functional impact of DLA-79*001:02. Ramachandran plots for the template (1Q94), reference (DLA-79*001:01), and DLA-79*001:02 models are shown in Online Resource 4. These plots demonstrate that the peptide-binding domain (residues 1-182) of both models are all within the allowable region; the only outliers are outside of the peptide binding domain. Global Qmean4 scores calculated by SWISS-MODEL were 0.591 for the wild type and 0.595 for the mutant model (Benkert et al. 2011) . These scores are within two standard deviations of previously solved protein structures of similar size.
Structural alignment of the DLA-79 models with HLA-A*1101 shows a high degree of homology at important peptide-interacting residues (Online Resource 5). One of the four conserved class I tyrosines (Y59) is identical in DLA-79, while the other three tyrosine positions (Y7, Y159, Y171) have conserved aromatic substitutions (F7, F160, H172 ). (The residue numbering for Y159 and Y171 is offset by one because DLA-79 has an additional residue (S82) near the Cterminus of the long alpha helix 1.) F33, as well the surrounding residues W51, I52/L52, and W167/W168 (HLA-A*1101/ DLA-79 numbering) are also conserved in HLA-A*1101.
We tested the assumption that the F33 change could affect peptide binding at the N-terminal peptide residue P1 using solvent mapping to evaluate differences in solvent binding between the wild-type and mutant proteins. In both models, multiple solvent clusters were identified at known sites which bind peptide side chains and anchor the peptide to the MHC molecule (Burnett and Geraghty 1995) . In the reference model, solvent mapping demonstrated clusters in the following binding sites: P1 (22 solvent molecules), P2 (15 solvent molecules), P3 (27 solvent molecules), and P9 (20 solvent molecules). In the DLA-79*001:02 model, solvent mapping demonstrated these same four clusters, but notably the change of F33 to L33 resulted in a solvent cluster that was no longer in hydrophobic contact with residue 33 (Fig. 4) .
We then evaluated whether the loss of this interaction could result in greater conformational flexibility for peptides at the P1 position by performing docking studies with two peptides identified by NetMHCpan that have hydrophobic residues at P1 (MMFASVLPALLL and VLMAGTFFF). The ten lowest energy complexes for each peptide were examined. The P1 position of these peptides adopts a much wider range of conformations in the mutant vs. the wild-type protein, nearly doubling the amount of permissible surface area occupied by this residue from 484 to 774 Å 2 for the methionine in MMFASVLPALLL and from 404 to 609 Å 2 for the valine in VLMAGTFFF (Fig. 5) . In all of the peptides, the C-terminal anchor remains intact.
Discussion
In this study, we demonstrate a strong association between the canine DLA-79*001:02 allele and multiple immune-mediated diseases in dogs. This allele results in two changes compared with the reference sequence, DLA-79*001:01. One of these changes (F33L) is located within the peptide binding pocket of the protein. Our computational modeling studies predict that this change may affect the interactions between DLA-79 and the N-terminus of peptides, creating increased flexibility at the P1 position. This flexibility may allow different peptides to bind the mutant vs. the wild-type DLA-79 and/or change the conformation in which peptides are presented on the cell surface. Given the complex nature of immune-mediated disease, however, we do not suggest that DLA-79 by itself is the causal candidate for all of the diseases evaluated. Rather, our findings suggest that DLA-79 or its downstream pathways may play a role in the pathogenesis of autoimmune disease, and that this role merits further study.
DLA-79 is a canine class Ib MHC protein whose specific role in the immune system is unknown. The secondary structure of the protein has been characterized, yet differences in the amino acid sequence vs. canine and orthologous class Ia proteins suggest that DLA-79 binds a unique set of peptides and may therefore have a distinct role in the immune response (Burnett and Geraghty 1995) . The protein has also been shown to be widely expressed in skeletal muscle, which is a unique feature compared with other MHC class I proteins (Burnett and Geraghty 1995) . Six alleles have been identified to date; however, none have been associated with any specific disease (Burnett and Geraghty 1995; Venkataraman et al. 2013) . Among a population of 407 healthy Beagles and a few mixed-breed dogs, 11.5 % were heterozygous for DLA-79*001:02 and 0.3 % of animals were homozygous for DLA-79*001:02 (Venkataraman et al. 2013) . These percentages correspond well with the DLA-79*001:02 allele frequency we found in healthy dogs but is much lower than the allele frequency we found in dogs with immune-mediated disease. However, it must be noted that the DLA-79*001:02 allele frequency described by Venkataraman et al. may not be representative of the allele frequency in the larger canine population. (Jiang et al. 1995 (Jiang et al. , 2005 . When lacking functional CD8 + T-regulatory cells, mice develop a systemic lupus erythematosus-like syndrome, suggesting a role for these class Ib molecules in the suppression of autoimmunity (Kim et al. 2011; McPhee et al. 2011 ). While our study does not offer mechanistic insights, the demonstrated association between DLA-79 and immune-mediated disease supports Additionally, it is noteworthy that the association between DLA-79*001:02 and immune-mediated disease is significant across all four disorders we evaluated despite some differences in their underlying pathophysiology. For example, IMHA and ITP are both type II autoimmune diseases in which an antibody response is generated against the cell membranes of erythrocytes or platelets, respectively (McCullough 2003; O'Marra et al. 2011) . IMPA is a type III autoimmune disease in which antigen-antibody complexes accumulate in the joint space and lead to ongoing inflammation (Johnson and Mackin 2012) . AD is an allergic syndrome caused by an aberrant immune response to an environmental exposure (Olivry et al. 2010; Nuttall et al. 2013 ). This suggests that DLA-79*001:02 may play a role in functions that are common across these diseases such as pathways which perpetuate an exuberant immune response. This role would be consistent with the previously described function of MHC class Ib genes in downregulating immune system effectors.
One limitation of the work presented here is the lack of precise balance between cases and controls by breed within our study population. We limited our study to 24 dog breeds where we had both case and control samples in an effort to mitigate breed bias; however, for some breeds, the numbers of samples available were small. Further studies that include a larger number of within-breed samples may be helpful in determining whether certain breeds that develop immune-mediated disease have a higher frequency of the DLA-79*001:02 allele. Nevertheless, canine immune-mediated diseases tend to cluster strongly within breeds and because non-genetic effects (e.g., environmental exposures, viruses) are likely to play a key role in the onset of these diseases, completely controlling for breed may be disadvantageous as it limits insights into diseasecausing mutations that may be fixed within breeds (Famula et al. 2003; Salzmann et al. 2011; Piek 2011; Bogdanos et al. 2012; Costenbader et al. 2012; Selmi et al. 2012; Catchpole et al. 2013) . Additionally, because of these non-genetic influences on phenotype, truly describing an animal as Bunaffected^is challenging as an animal that never develops clinical disease may in fact have a predisposing genetic variant but never have come in contact with a required environmental exposure.
Additionally, we cannot rule out that the association we have described between DLA-79*001:02 and autoimmune disease is in linkage disequilibrium with a more important causal variant. Studies that evaluate association between genetic polymorphisms and autoimmune disease on a genome-wide basis in dogs would be helpful in ruling out this possibility.
In summary, this study demonstrates an association between two tagging SNPs in DLA-79*001:02 and four common immune-mediated diseases in dogs. Based upon our computational modeling, the F33L mutation associated with this allele may alter key peptide-protein interactions. Changes in these key interactions may alter the downstream immune response and predispose dogs to developing certain immune-mediated diseases; however, further studies are required to definitively evaluate the impact of this polymorphism on protein function.
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